Last reviewed · How we verify
wIPV+bOPV
WIPV+bOPV is a vaccine that targets the SARS-CoV-2 virus.
WIPV+bOPV is a vaccine that targets the SARS-CoV-2 virus. Used for Prevention of COVID-19 caused by SARS-CoV-2.
At a glance
| Generic name | wIPV+bOPV |
|---|---|
| Sponsor | Beijing Minhai Biotechnology Co., Ltd |
| Drug class | Vaccine |
| Target | SARS-CoV-2 |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
WIPV+bOPV is a bivalent vaccine that combines the WIV04 and bivalent Omicron (BA.4/BA.5) protein subunits to provide immunity against SARS-CoV-2. This vaccine aims to stimulate the body's immune response to produce antibodies and immune cells that can recognize and fight the virus.
Approved indications
- Prevention of COVID-19 caused by SARS-CoV-2
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old Infants (PHASE3)
- A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a "2+1"Sequential Schedule With bOPV in Infants (PHASE3)
- A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in Infants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- wIPV+bOPV CI brief — competitive landscape report
- wIPV+bOPV updates RSS · CI watch RSS
- Beijing Minhai Biotechnology Co., Ltd portfolio CI